Stephen D. Chubb has been a Special Limited Partner of Catalyst Healthcare Ventures, a venture investment firm specializing in medical devices and diagnostic products, since June 2010. Mr. Chubb served as President and Chief Executive Officer of Allegro Diagnostics, Inc., a privately-held molecular diagnostics company focused on the development and future sale of innovative genomic tests for the diagnosis, staging and guided treatment of lung cancer and lung diseases, from September 2010 through March 2011. Mr. Chubb was previously Chairman and Chief Executive Officer of Matritech, Inc., a publicly-traded leading developer of proteomics-based diagnostic products for the early detection of cancer, from its inception in 1987 until December 2007. Mr. Chubb served as President and Chief Executive Officer of T Cell Sciences, Inc. and as President and Chief Executive Officer of Cytogen Corp., both publicly traded biotechnology companies. Mr. Chubb served as Chairman of the Board of Trustees of Mount Auburn Hospital in Cambridge, Massachusetts from 2006 to 2010 and was concurrently a director of Caregroup Healthcare System.
Dr. Milne began serving as a director of Amylyx in 2015. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. Milne has served on the Board of Directors at many different companies and organizations including currently Charles River Laboratories, Mettler-Toledo, Inc., BioStorage Technologies Inc., Draper Laboratory, the Sea Research Foundation, and the New York Botanical Garden. During his notable career, Milne has received a variety of honors, including an award from Yale University for lifetime contributions to commerce, innovation or education, the Connecticut College medal, and the distinguished citizen award from Big Brothers/Big Sisters. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.
Walter (Wally) Gilbert is a renowned scientist who was awarded the 1980 Nobel Prize in Chemistry for his discovery of a method for rapid DNA sequencing. His forty-year academic career at Harvard University was marked by many discoveries, including messenger RNA, genetic repressors, DNA sequencing, and the first expression of insulin in bacteria.
Dr. Gilbert is the Carl M. Loeb University Professor Emeritus at Harvard University. He is currently a managing director at BioVentures Investors, a venture capital fund in Cambridge, MA. In 1978 Dr. Gilbert co-founded Biogen, the world’s oldest independent biotechnology company. He served as Chair of the Scientific Board of Directors from 1978 to 1983, Co-Chairman of the Supervisory Board of Directors from 1979 to 1981, Chairman of the Supervisory Board of Directors from 1981 to 1985, and Chief Executive Officer from 1981 to 1985. As CEO, Dr. Gilbert oversaw the company’s Initial Public Offering in 1983 and played a key role in the development of several key products, including alpha interferon, beta interferon, and hepatitis B vaccine. In 1992, Dr. Gilbert co-founded Myriad Genetics and continues to serve as its Vice-Chairman. In 1996, Dr. Gilbert co-founded Paratek Pharmaceuticals and served as its Chairman until 2014.
Mr. Von Coerper began serving as a director of Amylyx in 2016. Mr. Von Coerper currently is the managing partner of the ALS Investment Fund, a venture capital fund based in the Netherlands exclusively focused on investment in promising ALS technologies. He has over 19 years experience in early stage venture management & finance. He founded a served as CEO of Elana and was CEO of MySample BV. He received his Masters in Economics from the Erasmus University Rotterdam.
Dr. Cheng joined Morningside in 2006 and focuses on biopharmaceutical and healthcare investments. He is currently a director of Liquidia Technologies, Cognoa, K-Gen, Artugen Therapeutics, Cognito Therapeutics, Amylyx Pharmaceuticals, and NuCana BioMed. Previously he was a board member of Advanced Cell Diagnostics (sold to Bio-Techne). Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company that was sold to Allergan. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Development and Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi at Massachusetts General Hospital / Harvard Medical School.
Dr. Walts is a Board Observer and Advisor to Amylyx. Alan has broad experience in the Life Science industry and serves as Executive Chairman of Aura Biosciences, Executive Chairman of Artax Biopharma, as a Director of X4 Pharmaceuticals and as a Director of Arrakis Therapeutics. Alan was a Business Advisor to the late Henri Termeer, and worked closely with Henri on founding and investing in early-stage companies. Alan is also a US-based Venture Partner with Advent Life Sciences. Alan has over 25 years of industry experience in venture capital, business development, research and development, and general management at Genzyme Corporation. Prior to leaving Genzyme in 2013, Alan managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi-Genzyme BioVentures). Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the Executive Program for Management Development at Harvard Business School.
Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University.
Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.
Paul Fonteyne began serving as a director of Amylyx in 2021. Mr. Fonteyne has more than thirty years of experience in the pharmaceutical industry, including in leadership positions focused on the commercialization of innovative treatments for patients around the globe. Most notably, he was with Boehringer Ingelheim for over 15 years where he served as the U.S. President and CEO for seven years, then subsequently Chairman until his retirement in January in 2019. During his tenure at Boehringer Ingelheim, Mr. Fonteyne helped drive the company’s annual top line sales in the USA significantly upwards and oversaw the successful U.S. launch of the company’s top selling products. Prior, he held commercial leadership roles at Merck and Co. Inc. from 1994-2003 and Abbott Laboratories from 1987-1995. He has served on the board of PhRMA, chaired the National Pharmaceutical Council and served as Chair of an American Cancer Society initiative for New England known as CEOs against Cancer. Mr. Fonteyne received an M.S. in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.
Mr. Termeer began serving as a board observer at Amylyx in 2016. He passed away on May 12th, 2017. Henri was an advocate for patients and an incredible mentor to the company. He was instrumental in helping Amylyx become a clinical-stage company and always impressed upon us the need to keep patients at the center of decisions. He will be sorely missed but we are thankful for the time we were able to spend with him.
For inquiries or further information, please do not hesitate to contact us.